EP delivery of pDNA coding for nanobodies against DR5, a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), resulted in more persistent serum levels of the anti-DR5, and consequently a more potent and durable anti-tumor activity in a colon cancer model than was observed with infusion of the purified protein [90]. This evidence concerns the gene TNFRSF10B and malignant colon neoplasm.